Cardiovascular disease in patients who have diabetes (Q35585956)

9 August 2017

1 reference

title

Cardiovascular disease in patients who have diabetes (English)

1 reference

9 August 2017

cardiovascular disease

1 reference

Cardiology and cardiovascular medicine

inferred from title

1 reference

https://api.crossref.org/works/10.1016/S0733-8651(03)00074-2

2 April 2024

author name string

Ronald B. Goldberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14621454

2 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14621454

2 April 2024

publication date

1 August 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S0733865103000742?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0733-8651(03)00074-2

https://api.elsevier.com/content/article/PII:S0733865103000742?httpAccept=text/plain

2 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0733-8651(03)00074-2

2 April 2024

1 reference

9 August 2017

21

1 reference

9 August 2017

399-413, vii

1 reference

9 August 2017

3

1 reference

Diabetes and cardiovascular disease. The Framingham study

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Diabetes and decline in heart disease mortality in US adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Biochemistry and molecular cell biology of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Body mass index, diabetes, and C-reactive protein among U.S. adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Coronary artery disease in IDDM. Gender differences in risk factors but not risk.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Adiponectin: a link between excess adiposity and associated comorbidities?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Nuclear Factor- B Suppressive and Inhibitor- B Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Impaired glucose tolerance--is it relevant for cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Hypertriglyceridemic hyperapoB in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

PPARS, metabolic disease and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Aspirin therapy in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2803%2900074-2

7 January 2021

Standards of medical care for patients with diabetes mellitus

25

1 reference

https://api.crossref.org/works/10.1016/S0733-8651(03)00074-2

Effect of pioglitazone on vascular reactivity in vivo and in vitro

2 April 2024

38

1 reference

https://api.crossref.org/works/10.1016/S0733-8651(03)00074-2

The importance of postprandial hyperglycaemia in development of cardiovascular disease in people with diabetes: point

2 April 2024

56

1 reference

https://api.crossref.org/works/10.1016/S0733-8651(03)00074-2

Management of dyslipidemia in adults with diabetes

2 April 2024

63

1 reference

https://api.crossref.org/works/10.1016/S0733-8651(03)00074-2

2 April 2024

Diabetic nephropathy

97

1 reference

https://api.crossref.org/works/10.1016/S0733-8651(03)00074-2

Aspirin therapy in diabetes

2 April 2024

105

1 reference

https://api.crossref.org/works/10.1016/S0733-8651(03)00074-2

2 April 2024

Identifiers

1 reference

9 August 2017

1 reference